<link rel='stylesheet' href='https//fonts.googleapis.com/css?family=Roboto:400,500,700,400italic|Material+Icons'>
Open Search
PTGX
Protagonist Therapeutics
$
()


  • Protagonist expects to reach VERIFY enrollment target by end of March

    3/26/2024 - 07:21am
  • Protagonist closes rusfertide license, collaboration agreement with Takeda

    3/18/2024 - 07:10am
  • Protagonist Therapeutics announces presentation of data on JNJ-2113

    3/11/2024 - 08:41am
  • Fly Intel: After-Hours Movers

    1/31/2024 - 18:51pm
  • Protagonist Therapeutics, Takeda enter into license agreement for Rusfertide

    1/31/2024 - 18:41pm
  • Capital One says buy these six biotech stocks for 2024

    1/25/2024 - 10:44am
  • Capital One reveals top six biotech picks for 2024

    1/25/2024 - 09:03am
  • Protagonist earns $10M payment for milestone in Phase 2b ANTHEM-UC study

    12/13/2023 - 07:40am
  • Protagonist Therapeutics reports two-year follow up data from REVIVE study

    12/12/2023 - 07:49am
  • Biotech Alert: Searches spiking for these stocks today

    12/8/2023 - 11:05am
  • Protagonist Therapeutics initiated with an Overweight at Capital One

    10/30/2023 - 07:03am
  • Protagonist Therapeutics announces advancement of JNJ-2113 across indications

    10/9/2023 - 07:10am
  • Protagonist Therapeutics price target lowered to $34 from $36 at JPMorgan

    9/25/2023 - 07:25am
  • Protagonist Therapeutics receives $34M from warrant exercises

    8/9/2023 - 07:53am
  • Protagonist Therapeutics management to meet with Piper Sandler

    7/11/2023 - 04:55am
dynamic_feed Breaking News